会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Oncogene, recombinant protein derived therefrom, and uses thereof
    • 癌基因,从其衍生的重组蛋白及其用途
    • US07358350B2
    • 2008-04-15
    • US10758562
    • 2004-01-16
    • Akira SaitoMasahiko Kuroda
    • Akira SaitoMasahiko Kuroda
    • C07H21/02C07H21/04
    • C07K14/82C07K16/32C12Q1/6886C12Q2600/136C12Q2600/158
    • The present invention identifies the total nucleotide sequence of a novel oncogene from human, which is directly involved in such a cancerization mechanism as for cervical cancer induced by HPV infection of cervical epithelial cell and the amino acid sequence of an oncogenic protein encoded thereby, and to provide a full-length polynucleotide encoding a peptide chain of the oncogenic protein derived from the novel oncogene, which can be used for recombinant production of the oncogenic protein, and the peptide chain of the oncogenic protein produced recombinantly therewith. Specifically, the present invention provides a novel oncogene polynucleotide from human involving development of cervical cancer, comprising a nucleotide sequence encoding an amino acid sequence of SEQ. ID. No.1, particularly a polynucleotide of the nucleotide sequence of SEQ. ID. No.2.
    • 本发明鉴定了来自人的新型致癌基因的总核苷酸序列,其直接参与由宫颈上皮细胞的HPV感染诱导的宫颈癌和由此编码的致癌蛋白的氨基酸序列的癌变机制, 提供编码衍生自新癌基因的致癌蛋白的肽链的全长多核苷酸,其可用于重组生成致癌蛋白质,以及重组产生的致癌蛋白质的肽链。 具体地,本发明提供了涉及宫颈癌发展的来自人的新型致癌基因多核苷酸,其包含编码SEQ ID NO:1的氨基酸序列的核苷酸序列。 ID。 1,特别是SEQ ID NO:1的核苷酸序列的多核苷酸。 ID。 2号
    • 2. 发明授权
    • Sirna capable of inhibiting the expression of an oncogene involved in cervical cancer
    • Sirna能够抑制参与宫颈癌的癌基因的表达
    • US07893246B2
    • 2011-02-22
    • US12207298
    • 2008-09-09
    • Akira SaitoMasahiko Kuroda
    • Akira SaitoMasahiko Kuroda
    • C07H21/04C12N15/11
    • C07K14/82C07K16/32C12Q1/6886C12Q2600/136C12Q2600/158
    • The present invention identifies the total nucleotide sequence of a novel oncogene from human, which is directly involved in such a cancerization mechanism as for cervical cancer induced by HPV infection of cervical epithelial cell and the amino acid sequence of an oncogenic protein encoded thereby, and to provide a full-length polynucleotide encoding a peptide chain of the oncogenic protein derived from the novel oncogene, which can be used for recombinant production of the oncogenic protein, and the peptide chain of the oncogenic protein produced recombinantly therewith. Specifically, the present invention provides a novel oncogene polynucleotide from human involving development of cervical cancer, comprising a nucleotide sequence encoding an amino acid sequence of SEQ. ID. No. 1, particularly a polynucleotide of the nucleotide sequence of SEQ. ID. No. 2.
    • 本发明鉴定了来自人的新型致癌基因的全部核苷酸序列,其直接涉及由HPV感染宫颈上皮细胞诱导的宫颈癌及其编码的致癌蛋白的氨基酸序列的癌化机制, 提供编码衍生自新癌基因的致癌蛋白的肽链的全长多核苷酸,其可用于重组生成致癌蛋白质,以及重组产生的致癌蛋白质的肽链。 具体地,本发明提供了涉及宫颈癌发展的来自人的新型致癌基因多核苷酸,其包含编码SEQ ID NO:1的氨基酸序列的核苷酸序列。 ID。 特别是SEQ ID NO:1的核苷酸序列的多核苷酸。 ID。 第2号。
    • 3. 发明申请
    • Novel oncogene, recombinant protein derived therefrom, and uses thereof
    • 癌基因,从其衍生的重组蛋白及其用途
    • US20060217342A1
    • 2006-09-28
    • US11449671
    • 2006-06-09
    • Akira SaitoMasahiko Kuroda
    • Akira SaitoMasahiko Kuroda
    • A61K48/00G01N33/574C07H21/02C07K14/82C07K16/30
    • C07K14/82C07K16/32C12Q1/6886C12Q2600/136C12Q2600/158
    • The present invention identifies the total nucleotide sequence of a novel oncogene from human, which is directly involved in such a cancerization mechanism as for cervical cancer induced by HPV infection of cervical epithelial cell and the amino acid sequence of an oncogenic protein encoded thereby, and to provide a full-length polynucleotide encoding a peptide chain of the oncogenic protein derived from the novel oncogene, which can be used for recombinant production of the oncogenic protein, and the peptide chain of the oncogenic protein produded recombinantly therewith. Specifically, the present invention provides a novel oncogene polynucleotide from human involving development of cervical cancer, comprising a nucleotide sequence encoding an amino acid sequence of SEQ. ID. No.1, particularly a polynucleotide of the nucleotide sequence of SEQ. ID. No.2.
    • 本发明鉴定了来自人的新型致癌基因的总核苷酸序列,其直接参与由宫颈上皮细胞的HPV感染诱导的宫颈癌和由此编码的致癌蛋白的氨基酸序列的癌变机制, 提供编码衍生自新癌基因的致癌蛋白的肽链的全长多核苷酸,其可用于重组生成致癌蛋白质,以及重组产生的致癌蛋白质的肽链。 具体地,本发明提供了涉及宫颈癌发展的来自人的新型致癌基因多核苷酸,其包含编码SEQ ID NO:1的氨基酸序列的核苷酸序列。 ID。 1,特别是SEQ ID NO:1的核苷酸序列的多核苷酸。 ID。 2号
    • 4. 发明申请
    • METHOD FOR EVALUATING CANCER
    • 癌症评估方法
    • US20120115139A1
    • 2012-05-10
    • US13265680
    • 2010-04-21
    • Masahiko KurodaAkira SaitoMaki Sano
    • Masahiko KurodaAkira SaitoMaki Sano
    • C12Q1/68
    • C12Q1/6886C12Q2600/112C12Q2600/118C12Q2600/158C12Q2600/178
    • Provided is a cancer evaluation method using a novel cancer marker for evaluating the onset, the preclinical stage, the clinical stage, or the prognosis of a cancer in a subject. At least one miRNA selected from hsa-miR-92 and hsa-miR-494 is used as the novel cancer marker in cancer evaluation. The cancer marker in a sample of a cell or a tissue is detected, and the possibility of a cancer in the sample is evaluated based on the expression level of the cancer marker. According to this evaluation method, by detecting the miRNA as the cancer marker, it becomes possible to evaluate the possibility of a cancer in the sample with excellent reliability. As a method for detecting the cancer marker, it is preferable to perform an in situ hybridization method using a labeled probe with respect to the sample that has been immobilized, for example.
    • 提供了一种使用新型癌症标志物评价受试者的癌症的发病,临床前期,临床阶段或预后的癌症评价方法。 使用至少一种选自hsa-miR-92和hsa-miR-494的miRNA作为癌症评价中的新型癌症标志物。 检测细胞或组织样品中的癌症标志物,并根据癌症标志物的表达水平评估样品中癌症的可能性。 根据该评价方法,通过检测miRNA作为癌症标记物,可以以极好的可靠性来评价样品中癌症的可能性。 作为检测癌症标记物的方法,优选使用例如相对于被固定化的样品的标记探针进行原位杂交法。
    • 9. 发明申请
    • PROCESSING TARGET REFORMING APPARATUS, PRINTING APPARATUS, PRINTING SYSTEM, AND METHOD
    • 加工目标改造设备,印刷设备,印刷系统和方法
    • US20150076124A1
    • 2015-03-19
    • US14486919
    • 2014-09-15
    • Kengo TsubakiYoshiyuki ArasekiAkira Saito
    • Kengo TsubakiYoshiyuki ArasekiAkira Saito
    • B23K10/00B23K9/28
    • B41J2/06B41J11/0015H05H1/2406H05H1/46H05H2001/2412H05H2001/4682
    • A processing target reforming apparatus includes: a conveying unit that conveys a processing target along a conveyance path; a discharge unit including a plurality of discharge electrodes aligned along the conveyance path, a counter electrode with the conveyance path interposed therebetween, and a power source that applies a voltage waveform to the discharge electrodes; and a control unit that controls the discharge unit such that a phase of the voltage waveform applied to a first discharge electrode of the discharge electrodes at a timing when a certain point of the processing target passes between the first discharge electrode and the counter electrode is shifted with respect to a phase of the voltage waveform applied by the power source to a second discharge electrode of the discharge electrodes at a timing when the certain point of the processing target passes between the second discharge electrode and the counter electrode.
    • 一种加工对象重整装置,包括:输送单元,其沿着输送路径输送加工对象物; 放电单元,包括沿着输送路径排列的多个放电电极,具有介于其间的输送路径的对置电极和向放电电极施加电压波形的电源; 以及控制单元,其控制所述放电单元,使得在所述处理对象的某一点在所述第一放电电极和所述对置电极之间通过的时刻的施加到所述放电电极的第一放电电极的电压波形的相位偏移 相对于处理对象的特定点在第二放电电极和对电极之间通过的时刻,由电源对放电电极的第二放电电极施加的电压波形的相位。